Log In
BCIQ
Print this Print this
 

OPS201, SOMther

  Manage Alerts
Collapse Summary General Information
Company Ipsen Group
DescriptionRadionuclide therapy labeled with yttrium-90 or lutetium-177 that antagonizes somatostatin receptor 2 (SSTR2)
Molecular Target Somatostatin receptor 2 (SSTR2)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat neuroendocrine tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$56.6M

$34.0M

$22.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/30/2015

$56.6M

$34.0M

$22.6M

Get a free BioCentury trial today